Evaluating the Validity of a Genetic Risk Assessment Tool in Identifying Autism Spectrum Disorder

NCT01452061 | Completed

• 1 other identifier: CCF 11-949
• Study Type: observational
• Target: 456
• Locations: 1 country
• Sites: 1

Brief Summary

There are three purposes to this study. The first purpose is to evaluate the value of a genetic test in determining risk for autism spectrum disorder. Processing for genetic samples will be completed at the Cleveland Clinic using research equipment provided by IntegraGen. The second purpose is to identify genetic changes that may be associated with autism spectrum disorder or attention deficit/hyperactivity disorder. The third purpose is to examine whether genetic differences and changes may predict which individuals benefit from medicine used to treat attention problems or other psychiatric difficulties. Between 600-800 people are expected to participate in this study - approximately 300 individuals with an autism spectrum disorder, 75 individuals with attention deficit/hyperactivity disorder or another developmental or psychiatric disorder, 100 healthy siblings, and 125 unrelated individuals without a developmental or psychiatric disorder. Study procedures will vary based upon the specific group participants are suspected to fall into (autism, attention deficit/hyperactivity disorder, psychiatric concerns/developmental delay, healthy sibling, or unrelated healthy control).

• All individuals will be asked to participate in a cheek swab (gently swabbing the inside of your cheek) to obtain cells used for genetic testing. Genetic material will be stored with identifiers such as numbers, letters or codes.
• Parents or caregivers will be asked to complete questionnaires that examine medical and family history as well as current symptoms and quality of life for the participant.
• Participants may undergo speech and language testing. This involves answering questions, looking at pictures or identifying items.
• Information recorded in participant medical records will be reviewed and collected for this study.

Conditions

Autism Spectrum Disorder; Attention Deficit/Hyperactivity Disorder; Developmental Delay

Keywords

Autism Spectrum Disorder; Attention Deficit/Hyperactivity Disorder; Developmental Delay

Outcome Measures

Primary Outcomes (1)

• Autism Spectrum Disorder clinical diagnosis

  March 2014

Study Arms (4)

ASD

Participants with autism spectrum disorder.

ADHD/DD

Participants with attention deficit/hyperactivity disorder, developmental delay or psychiatric disorder.

Siblings

Siblings without a developmental or psychiatric disorder.

Control

Unrelated individuals without a developmental or psychiatric disorder.

Eligibility Criteria

• Age: 1 Year - 12 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

About 600 people will take part in this study - 300 individuals with an autism spectrum disorder, 75 individuals with attention deficit/hyperactivity disorder or another developmental or psychiatric disorder, 100 healthy siblings, and 125 unrelated individuals without a developmental or psychiatric disorder.

You may qualify if:

• Diagnosis of Autistic Disorder, Pervasive Developmental Disorder, or Asperger's Disorder or have a clinical diagnosis of another developmental or psychiatric disorder (developmental/psychiatric controls), or have no specific developmental or psychiatric diagnosis (healthy controls).
• Age 1 to 12.

You may not qualify if:

• For individuals with ASD and developmental concern controls, presence of a known or strongly suspected genetic disorder based on all available clinical data.
• Age less than 1 or greater than 12.
• Individuals for whom DNA is not available for analysis.
• Individuals for whom it is anticipated that they will not be available for follow-up at the Cleveland Clinic during the study period.
• Any medical diagnoses that might preclude participation in a low risk, non-interventional research study and any participant who at the discretion of the clinical investigator is not medically able to participate in the study (e.g., unable to comply with cheek swab or other procedure or has serious medical condition which precludes participation).

Sponsors & Collaborators

• Thomas W. Frazier, Ph.D: lead
• IntegraGen SA: collaborator

Study Sites (1)

Cleveland Clinic Center for Autism

Cleveland, Ohio, 44104, United States

Location

Related Links

• Cleveland Clinic Center for Autism Research Website

Biospecimen

Retention: SAMPLES WITH DNA

Genetic material via a cheek swab will be collected.

MeSH Terms

Conditions

Autism Spectrum Disorder; Attention Deficit Disorder with Hyperactivity; Learning Disabilities

Condition Hierarchy (Ancestors)

Child Development Disorders, Pervasive; Neurodevelopmental Disorders; Mental Disorders; Attention Deficit and Disruptive Behavior Disorders; Communication Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Officials

• Thomas W Frazier, Ph.D.

  The Cleveland Clinic

  PRINCIPAL INVESTIGATOR

• Charis Eng, M.D., Ph.D.

  The Cleveland Clinic

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Center for Autism Research Director

Study Record Dates

• First Submitted: October 11, 2011
• First Posted: October 14, 2011
• Study Start: January 1, 2012
• Primary Completion: December 1, 2013
• Study Completion: December 1, 2013
• Last Updated: January 29, 2014

Record last verified: 2014-01

Locations

US (1)